Renin angiotensin system blockade and nephropathy: why is it being called into question, and should it be?
Hollenberg
Norman K
NK
Department of Radiology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA. djpagecapo@rics.bwh.harvard.edu
Epstein
Murray
M
D047228:Angiotensin II Type 1 Receptor Blockers / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000379:methods; D003928:Diabetic Nephropathies / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007676:Kidney Failure, Chronic / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D015201:Meta-Analysis as Topic; D012084:Renin-Angiotensin System / Q000187:drug effects*; D012107:Research Design; D013997:Time Factors
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors